1-3 of 3
Narinder Janghra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies

Francesca Zammarchi, Karin E. Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, Francois Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A. Hartley, Patrick H. van Berkel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (4): 520–531.
https://doi.org/10.1158/1535-7163.MCT-23-0506
Published: 02 April 2024
View articletitled, ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Open the PDF for ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers

Francesca Zammarchi, Karin EG. Havenith, Simon Chivers, Paul Hogg, Francois Bertelli, Peter Tyrer, Narinder Janghra, Halla W. Reinert, John A. Hartley, Patrick H. van Berkel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 582–593.
https://doi.org/10.1158/1535-7163.MCT-21-0715
Published: 01 April 2022
View articletitled, Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers
Open the PDF for Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers in another window
Includes: Supplementary data
Journal Articles

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Michael J. Flynn, Francesca Zammarchi, Peter C. Tyrer, Ayse U. Akarca, Narinder Janghra, Charles E. Britten, Carin E.G. Havenith, Jean-Noel Levy, Arnaud Tiberghien, Luke A. Masterson, Conor Barry, Francois D'Hooge, Teresa Marafioti, Paul W.H.I. Parren, David G. Williams, Philip W. Howard, Patrick H. van Berkel, John A. Hartley
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (11): 2709–2721.
https://doi.org/10.1158/1535-7163.MCT-16-0233
Published: 01 November 2016
View articletitled, ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Open the PDF for ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies in another window
Includes: Supplementary data